The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-A real-world practice
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the Chinese Medical Association"
DOI: 10.1097/jcma.0000000000000768
Abstract: Background: Bacillus Calmette–Guérin (BCG) has been well recognized as the first-line intravesical therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). Oncotice, the Tice strain of BCG, serves as a viable alternative to the Connaught strain owing… read more here.
Keywords: tice; pfs; non muscle; urothelial carcinoma ... See more keywords
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14040887
Abstract: Simple Summary Intravesical immunotherapy with bacillus Calmette–Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer. Different BCG strains are currently available and the superiority of any BCG strain over another could not… read more here.
Keywords: bcg tice; tice; high risk; rivm ... See more keywords